Eli Lilly and Company, Thermo Fisher Scientific, Merck & Co., Inc., AbbVie, Johnson & Johnson, Colgate-Palmolive, and Bristol-Myers Squibb are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, or market prescription drugs, vaccines, and related medical treatments. Investors buy these stocks to gain exposure to the pharmaceutical industry’s growth potential, which is influenced by factors such as drug approvals, patent expirations, regulatory changes, and global healthcare demand. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
NYSE LLY traded up $26.04 during trading on Thursday, reaching $855.46. 1,571,490 shares of the company's stock traded hands, compared to its average volume of 3,750,576. The company's 50 day simple moving average is $826.81 and its two-hundred day simple moving average is $819.07. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm has a market cap of $811.12 billion, a price-to-earnings ratio of 73.06, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51.
Read Our Latest Research Report on LLY
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
NYSE TMO traded down $11.05 during trading hours on Thursday, reaching $420.60. The stock had a trading volume of 2,151,689 shares, compared to its average volume of 2,172,052. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market cap of $158.77 billion, a P/E ratio of 25.42, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The stock has a fifty day moving average of $491.37 and a 200 day moving average of $530.03. Thermo Fisher Scientific has a 52-week low of $409.85 and a 52-week high of $627.88.
Read Our Latest Research Report on TMO
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Shares of NYSE MRK traded up $0.26 during mid-day trading on Thursday, reaching $79.00. The company's stock had a trading volume of 10,981,119 shares, compared to its average volume of 16,247,504. Merck & Co., Inc. has a 1-year low of $75.93 and a 1-year high of $134.63. The stock has a market capitalization of $199.22 billion, a P/E ratio of 11.73, a P/E/G ratio of 0.77 and a beta of 0.40. The stock has a 50-day moving average of $87.12 and a two-hundred day moving average of $95.61. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36.
Read Our Latest Research Report on MRK
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE ABBV traded up $2.72 during trading on Thursday, hitting $179.77. The stock had a trading volume of 4,404,975 shares, compared to its average volume of 7,122,350. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. AbbVie has a twelve month low of $153.58 and a twelve month high of $218.66. The company has a market capitalization of $318.01 billion, a PE ratio of 74.92, a PEG ratio of 1.62 and a beta of 0.55. The firm has a 50 day moving average price of $197.30 and a 200 day moving average price of $187.37.
Read Our Latest Research Report on ABBV
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
NYSE:JNJ traded down $0.92 during trading hours on Thursday, hitting $154.46. The company's stock had a trading volume of 4,221,731 shares, compared to its average volume of 9,776,516. The stock has a fifty day moving average of $159.52 and a 200-day moving average of $154.95. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $372.23 billion, a P/E ratio of 23.22, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49.
Read Our Latest Research Report on JNJ
Colgate-Palmolive (CL)
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.
NYSE CL traded down $1.01 on Thursday, reaching $92.88. The stock had a trading volume of 6,213,702 shares, compared to its average volume of 5,379,294. Colgate-Palmolive has a 12-month low of $85.32 and a 12-month high of $109.30. The stock has a market cap of $75.33 billion, a P/E ratio of 26.37, a price-to-earnings-growth ratio of 4.20 and a beta of 0.40. The business's 50-day moving average price is $91.78 and its 200 day moving average price is $92.31. The company has a debt-to-equity ratio of 13.40, a quick ratio of 0.58 and a current ratio of 0.92.
Read Our Latest Research Report on CL
Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Shares of NYSE:BMY traded down $0.07 during midday trading on Thursday, hitting $48.46. The stock had a trading volume of 11,852,924 shares, compared to its average volume of 12,466,562. The company has a market capitalization of $98.60 billion, a PE ratio of -10.96, a P/E/G ratio of 2.07 and a beta of 0.41. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The stock has a 50 day moving average price of $56.60 and a two-hundred day moving average price of $56.54. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90.
Read Our Latest Research Report on BMY
Recommended Stories
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
